[bioundgrd] Fwd: Biomatrix/BUSA Lunch with David Berry

[Janice Chang]

>From: Dima Ter-Ovanesyan <dter at MIT.EDU>
>Subject: Biomatrix/BUSA Lunch with David Berry
>
>
>
>Biomatrix and Biology Undergraduate Student Association (BUSA) Present:
>
>Leaders in Life Science Lunch Series (Rescheduled from February)
>
>Lunch with David Berry, Partner at Flagship Ventures
>
>Learn about Entrepreneurship in the life sciences and the application of
>synthetic biology to the energy problem from an MIT Alum (full bio below).
>
>Date: Friday, March 19, 2010
>Time:  12:00-1:00 PM
>
>Open to undergrads of all majors.
>
>Space is limited. RSVP to dter at mit.edu
>
>Bio:
>David Berry is a Partner at Flagship Ventures, having joined Flagship in 2005
>while completing his M.D. from Harvard Medical School. David was previously
>awarded a Ph.D. through the MIT Biological Engineering Division, where he
>studied the biological effects of complex sugars with advisors Professor Ram
>Sasisekharan and Professor Robert Langer. David also did his 
>undergraduate work
>at MIT, graduating in 2000 Phi Beta Kappa and Sigma Xi, with a degree in brain
>and cognitive sciences. He was named as a member of the MIT Corporation - its
>Board of Trustees - in 2006. David's work has led to 11 peer-reviewed
>publications, over 20 patents and applications, as well as over twenty-five
>awards and honors including the prestigious Lemelson-MIT Student Prize in 2005
>for invention and innovation. David was also named as the Innovator 
>of the Year
>by Technology Review in its 2007 TR35 list of world?s top 35 innovators under
>the age of 35.
>
>At Flagship, David focuses on investing in and founding early stage 
>life science
>and cleantech ventures. In 2005, he co-founded and helped launch LS9, and more
>recently co-founded Joule Biotechnologies where he previously served as the
>founding CEO. In addition, David serves on the Board of Directors of CGI
>Pharmaceuticals and Eleven Biotherapeutics and works closely with 
>several other
>portfolio companies.